Have Novo Nordisk shares got further to go? This investment bank has its say

Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA, and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note. Novo Nordisk is highlighted for its exceptional growth outlook, with analysts anticipating over 20% growth in 2024, distinct from its big pharma peers. Key drivers for this growth include the potential approval of a weekly insulin product and new data for semaglutide (Ozempic/Wegovy) in heart failure-preserved ejection ...